期刊文献+

难治性急性髓系白血病预后因素分析 被引量:1

Analysis of prognostic factors in patients with refractory acute myeloid leukemia
下载PDF
导出
摘要 目的分析难治性急性髓系白血病(AML)的预后因素,为难治性AML治疗方案的选择提供理论基础。方法选取接受了2个标准DA方案诱导治疗的48例复发性难治性AML患者,分析患者年龄、性别、对标准诱导治疗的反应,遗传学异常、骨髓中白血病细胞比例、外周血情况、髓外浸润以及乳酸脱氢酶(LDH)等因素对患者生存期的影响。结果经Cox回归分析显示,患者在标准诱导治疗后达到完全缓解、缓解期大于6个月、有较好预后的细胞遗传学异常、骨髓白血病细胞比例小于50%、无严重贫血、无肝脾肿大和中枢神经系统白血病、血清LDH小于360 U/L者预后较好;而年龄、性别、外周血白细胞总数以及淋巴结肿大对患者生存期无明显影响。结论对于有较好预后因素的AML患者应给予积极的治疗,争取较长的持续缓解期;对于预后差的病例应尽快予以异基因骨髓移植。 Objective To analyze the prognostic factors in patients with refractory acute myeloid leukemia, so as to provide theoretical basis for choosing an appropriate chemotherapy. Methods This study included 48 patients with refractory acute myeloid leukemia who received two standard DA regimens followed by chemotherapy with median dose of Ara-C and mitox-antrone. The factors such as age, gender, responses to the standard chemotherapy, cytogenetic abnormalities, blast cell counts in the bone marrow, peripheral blood cell counts, extramedullary infiltration exhibition and LDH were examined in light of their respective impact on the patients' survival. Cox regression model was used to analyze the prognostic factors. Results The results revealed that the factors such as achievement of the first complete remission after standard induction chemothera-py, the remission duration longer than 6 months, favorable cytogenetic abnormalities, blast cell counts less than 50% in bone marrow, absence of severe anemia, absence of liver or pancreatic enlargement or central nerves system (CNS) leukemia, and LDH less than 360 U/L, all indicated favorable prognosis of the patients. Age, gender, white cell counts in periphery blood or lymphadenopathy were not related to the survival of the patients. Conclusion The patients with favorable prognostic factors should receive intensive chemotherapy for prolonged survival; allogeneic bone marrow transplantation should be performed as soon as possible in patients with unfavorable prognostic factors.
出处 《第一军医大学学报》 CSCD 北大核心 2003年第9期934-936,共3页 Journal of First Military Medical University
基金 国家自然科学基金(39770831) 广东省自然科学基金(970833)~~
关键词 难治性急性髓系白血病 预后 治疗 骨髓移植 阿糖胞苷 米托蒽醌 acute myeloid leukemia, refractory/prognosis Cox regression analysis bone marrow transplantation, allogeneic
  • 相关文献

参考文献10

  • 1徐丹,孟凡义,张燕.血管内皮生长因子在急性髓系白血病细胞中的表达[J].第一军医大学学报,2002,22(4):357-359. 被引量:7
  • 2杜庆锋,刘晓力,宋兰琳,张嵩,周淑芸.155例髓系白血病细胞遗传学分析与临床关系探讨[J].第一军医大学学报,2002,22(10):905-907. 被引量:2
  • 3杜庆锋,刘晓力,刘启发,李荣,陈琪,周淑芸.定量分析两种治疗方案与危险指数对慢性髓系白血病临床缓解率的影响[J].第一军医大学学报,2002,22(8):729-730. 被引量:1
  • 4李荣,刘晓力,杜庆锋,田红,宋兰林,张燕,杨艺,周淑芸.三尖杉酯碱诱导慢性髓系白血病K-562细胞凋亡的实验研究[J].第一军医大学学报,2002,22(9):788-790. 被引量:6
  • 5Bennet JM, Catovsky D, Daniel Mr, et al.Proposal revised criteria for the classification of acuteJmyeloid leukemia: a report of the France-America-British cooperative group[J]. Ann Intcxn Med,1985, 103(4): 620-5.
  • 6Yates J, Glidewell O, Wiemik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia:a CALGB study[J]. Blood, 1982, 60(2): 454-62.
  • 7Kern W, Schoch C, Haferlach T, et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities[J]. Leukemia, 2000, 14(2): 226-31.
  • 8Giles FJ, Keating A, Goldstione AH, et al. Acute myeloid leukemia[J]. Hematology, 2002, 7(1): 73-110.
  • 9Valet G, Repp R, Link H, et al. Pretherapeutic identification of high risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters[J]. Cytometry, 2003, 5313(1):4-10.
  • 10Stone RM. The difficult problem of acute myeloid leukemia in the older adult[J]. CA Cancer J Clin, 2002, 52(6): 363-71.

二级参考文献18

  • 1郑维扬,周淑芸,王小琪,孙竞.筑巢式PCR检测白血病微量残留bcr/ablmRNA[J].中华血液学杂志,1994,15(5):227-229. 被引量:31
  • 2刘元波,郝玉书,卞寿庚,钱林生.慢性粒-单核细胞白血病临床及血液学特征鉴定——附35例分析[J].中华血液学杂志,1996,17(12):629-633. 被引量:9
  • 3徐兵,周淑芸.HA方案剂量个体化治疗老年人慢性粒细胞性白血病[J].第一军医大学学报,1997,17(1):10-11. 被引量:2
  • 4张之南.血液病诊断与疗效标准[M].天津:天津科技出版社,1991.225-232.
  • 5瞿群华 熊金元 等.三尖杉酯碱和阿糖胞苷方案治疗慢性粒细胞白血病18例[J].中华内科杂志,1994,33(5):305-305.
  • 6Aguayo A,Estey E,Kantarjian H,et al.Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia[J].Blood,1999,94: 3717-21.
  • 7Veiga JP,Afonso H,Sallan SE,et al.Acute lymphoblastie leukemia cells and their bone marrow stroma collaborate to induce endothelial cell proliferation thereby promoting leukemia cell survival [J].Blood,1998,92 (Suppl)10:511a.
  • 8Fiedler W,Gracven U,Ergun S,et al.Vascular endothelial growth factor,a possible paracrine growth factor in human acute myeloid leukemia[J].Blood,1997,89(6): 1870-6.
  • 9Tischer E,Mitchell R,Hartman T,et al The human gene for vascular endothelial growth factor[J].J Biol Chem,1991,266:11947-54.
  • 10WalterF,Ullrieh G,Suleyman E,et al.Vascular endothelial growth factor,a possible paracrine growth factor in human acute myeloid leukemia[J].Blood,1997,83: 1870-75.

共引文献12

同被引文献20

  • 1刘启发,张钰,魏永强,徐丹,孙竞,徐兵,刘晓力,冯茹,孟凡义,周淑芸.造血干细胞移植治疗恶性血液病疗效分析[J].肿瘤防治研究,2004,31(6):356-358. 被引量:4
  • 2吴祥元,黄仁魏,李铭权,肖若芝,杨万里,林东军.造血干细胞移植治疗成人急性白血病[J].中国肿瘤临床,1997,24(4):294-297. 被引量:3
  • 3Godder K, Eapen M, Laver JH, et al. Autologous hematopoietic stem-celt transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis. J Clin Oncol 2004:22(18):3798-3804.
  • 4Hallemeier C, Girgis M, Blum W, et al. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Bone Marrow Transplant 2004;10(5): 310-319.
  • 5Heinzelmann F, Ottinger H, Muller CH, et al. Total-body irradiation--role and indications: results from the German Registry for Stem Cell Transplantation (DRST). Strahlenther Onkol 2006: 182(4): 222-230.
  • 6Mamlouk K, Saracino G, Berrym an RB, et al. Modification of the Bu/Cy myeloablative regimen using daily parentera! busulfan: reduced toxicity without the need for pharmacokinetic monitoring. Bone Marrow Transplant 2005: 35(8): 747-754.
  • 7Gil L, Styczynski J, Komarnicki M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection 2007. 35(6): 421-427.
  • 8Lange B J, Dinndorf P, Smith FO, et al. Pilot study of idarubicin based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941. J Clin Oneol 2004;22(1): 150-156.
  • 9Woods WG Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group. Blood 2001;97(1): 56-62.
  • 10Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AMI-BFM trials. Leukemia 2005: 19(12): 2030-2042.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部